Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience.

J Clin Endocrinol Metab · 2023 · PMC10655523 · PMID 37357993

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

borderline significanceP = .06so close (0.05 < p ≤ 0.1)

Weight at initiation of pasireotide was similar between controlled and uncontrolled patients, whereas controlled patients had lower body mass index (BMI) with borderline significance ( P = .06).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.